Comparative Pharmacology
Head-to-head clinical analysis: IV PERSANTINE versus THEROXIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IV PERSANTINE versus THEROXIDIL.
IV PERSANTINE vs THEROXIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits adenosine deaminase and phosphodiesterase, increasing intracellular cAMP and adenosine; causes coronary vasodilation and inhibits platelet aggregation.
Theroxidil is a vasodilator that acts by opening potassium channels in vascular smooth muscle, leading to hyperpolarization and relaxation. It also inhibits platelet aggregation and reduces peripheral vascular resistance.
0.14 mg/kg/min intravenous infusion over 4 minutes for myocardial perfusion imaging.
5 mg orally once daily, increased to 10 mg after 4 weeks as tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in adults; may be prolonged in patients with hepatic impairment.
Terminal elimination half-life 24-30 hours; steady-state reached after 4-5 days; clinically significant for once-daily dosing
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; renal excretion of unchanged drug is minimal (<1%); biliary/fecal elimination accounts for approximately 90% of the dose.
Approximately 60% renal (15% unchanged, 45% as glucuronide metabolites), 40% fecal/biliary as metabolites
Category C
Category C
Vasodilator
Vasodilator